The gut is one of the least discussed but most consequential targets of nicotine’s physiological reach. Nicotinic acetylcholine receptors are expressed throughout the enteric nervous system — the gut’s own intrinsic neural network — and the interaction between nicotine, intestinal motility, mucosal immunity and the gut microbiome creates a complex picture that is highly relevant to the millions of people who vape daily. For users of any format, from pod systems to rechargeable vapes, understanding how absorbed nicotine and aerosol compounds reach and alter gastrointestinal biology fills an important gap in the harm reduction conversation.
The Enteric Nervous System and Nicotinic Receptors
The enteric nervous system (ENS) — sometimes called the “second brain” — is a vast network of approximately 100 million neurons embedded in the walls of the gastrointestinal tract, from oesophagus to rectum. The ENS controls intestinal motility (the coordinated muscular contractions that move food and waste), regulates fluid secretion into the gut lumen, and coordinates communication with the central nervous system via the vagus nerve. Nicotinic acetylcholine receptors (nAChRs) are expressed abundantly throughout the ENS on both excitatory and inhibitory neurons, as well as on enteric smooth muscle cells and intestinal epithelial cells.
When nicotine enters the bloodstream — whether from cigarettes, nicotine replacement therapy, or vaping — it activates these ENS nAChRs in ways that alter gastrointestinal function. The acute effects of nicotine on the gut are well-characterised from smoking research: increased gastric acid secretion, altered lower oesophageal sphincter tone, changes in colonic motility, and modulation of the intestinal immune response. These effects are delivery-method independent — they occur whenever nicotine reaches the ENS, regardless of whether it arrives via the lungs from aerosol or via oral mucosa from a nicotine pouch.
Nicotine and Intestinal Motility
Nicotine’s effects on gut motility are paradoxical and region-dependent. In the upper gastrointestinal tract, nicotine activates excitatory nAChRs on esophageal and gastric smooth muscle, increasing lower oesophageal sphincter (LOS) tone transiently before relaxing it — the relaxation phase is associated with the increased gastro-oesophageal reflux (heartburn) documented in both smokers and, to a lesser degree, vapers. The increased gastric acid secretion from nicotine-stimulated parietal cells compounds this reflux risk.
In the colon, nicotine’s motility effects are primarily excitatory — it accelerates colonic transit through activation of cholinergic motor pathways in the ENS. This colonic stimulant effect is why many smokers report bowel movements shortly after their first cigarette of the day, and why nicotine withdrawal is associated with constipation in some individuals. The practical implication for vapers is that these transit effects persist with nicotine delivery via e-cigarette and can be clinically relevant for people with pre-existing irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD).
Inflammatory Bowel Disease: A Special Case
The relationship between nicotine and inflammatory bowel disease is one of the most counterintuitive findings in gastroenterology. Epidemiological studies established decades ago that smoking has divergent effects on the two major forms of IBD: it appears to be protective against ulcerative colitis (UC) — with smokers having lower rates of active UC and milder disease when it occurs — while simultaneously worsening Crohn’s disease outcomes significantly.
The UC paradox has generated considerable research interest. The leading explanation involves nicotine’s cholinergic anti-inflammatory pathway (via α7-nAChR, discussed in the immune system companion article): by reducing colonic mucosal inflammation through the same mechanism that broadly suppresses immune responses, nicotine appears to have a disease-modifying effect specifically in UC, where excessive mucosal inflammation is the core pathology. Several clinical trials using nicotine patches for active UC showed modest benefit, providing direct clinical evidence for this anti-inflammatory mechanism. Vaping-delivered nicotine activates the same pathway and theoretically carries similar implications for UC biology — though no clinical trials of vaping specifically in UC management have been conducted.
For Crohn’s disease, the picture is the reverse: smoking is associated with more frequent relapses, more steroid-dependent disease, higher rates of surgical resection, and worse long-term outcomes. The mechanisms involve nicotine’s effects on intestinal permeability, altered mucosal immunity, and changes in the gut microbiome that favour pro-inflammatory species. Whether vaping produces equivalent Crohn’s disease worsening, or a lesser effect due to the absence of combustion-specific intestinal toxins, is not established by direct clinical data — but the shared nicotine mechanisms are a reasonable basis for caution.
Clinical implication for IBD patients: if you have ulcerative colitis and are considering stopping nicotine use, be aware that some patients experience a UC flare in the weeks following nicotine cessation — the disease may have been partially controlled by the nicotine-mediated anti-inflammatory effect. Discuss any nicotine cessation plan with your gastroenterologist before implementing it. For Crohn’s disease patients, nicotine minimisation is unambiguously the recommended direction.
The Gut Microbiome: Nicotine’s Reach into the Microbial Community
The human gut microbiome — the community of approximately 38 trillion bacteria, archaea, fungi and viruses inhabiting the gastrointestinal tract — is one of the most active areas of biomedical research and one of the most significant determinants of metabolic, immune and gastrointestinal health. Smoking has well-documented adverse effects on gut microbiome composition, reducing species diversity (a marker of a healthy microbiome), depleting beneficial Lactobacillus and Bifidobacterium species, and enriching potentially pathogenic species associated with inflammation and metabolic disease.
The mechanisms through which nicotine and vaping alter the gut microbiome are multiple. Nicotine itself has direct antimicrobial activity — it inhibits the growth of certain bacterial species while sparing others, creating a selection pressure that shifts community composition. Nicotine also alters intestinal mucus production and composition, which functions as the habitat in which mucus-adherent microbiome communities live. Changes in intestinal motility from nicotine use alter the transit time that determines which bacterial species can establish and maintain populations in different gut regions.
A 2019 study in Gut Microbes examining the microbiomes of vapers, smokers and non-users found that vapers had intermediate microbiome composition between smokers and non-users — closer to non-users than smokers on most diversity metrics, but with some specific compositional differences from both groups. This pattern is consistent with the removal of combustion-specific microbial disruptors while nicotine-specific effects on the microbiome persist. The long-term clinical significance of vaping-specific microbiome alterations is not yet established, but the direction of effect — partial improvement compared to smoking — is consistent with the general harm reduction narrative.
Gastrointestinal Cancers: The Smoking Connection and Vaping’s Position
Smoking is a well-established risk factor for cancers of the oesophagus (both squamous and adenocarcinoma subtypes), stomach, pancreas, liver and colorectum. The mechanisms are multiple: direct carcinogen exposure from swallowed tobacco compounds, nicotine-induced gastro-oesophageal reflux creating chronic mucosal injury, altered gut microbiome composition influencing carcinogenesis-related microbial metabolites, and systemic inflammatory and oxidative stress effects.
Vaping eliminates the direct carcinogen exposure from combustion products — a significant proportion of the gastrointestinal cancer risk from smoking is attributable to compounds that simply are not present in e-cigarette aerosol. The nicotine-specific contributions to GI carcinogenesis risk — via nicotine’s effects on cell proliferation, angiogenesis, and the tumour microenvironment — are shared, but at a level that represents a partial risk reduction rather than complete elimination. The gastro-oesophageal reflux risk from nicotine-mediated LOS relaxation is also shared across delivery methods, making management of reflux symptoms relevant regardless of whether nicotine is delivered by cigarette or vape.
Practical Guidance for Vapers Concerned About Gut Health
- If you experience increased heartburn, regurgitation or reflux symptoms while vaping, discuss these with a GP — this is the most commonly reported gastrointestinal symptom among vapers and is directly attributable to nicotine’s effect on lower oesophageal sphincter tone. Dietary modification, timing of vaping relative to meals, and proton pump inhibitor therapy if appropriate can all help manage this.
- If you have IBD, discuss your vaping status explicitly with your gastroenterologist. For UC patients, any plans to reduce or stop nicotine should be coordinated with your GI specialist to anticipate and manage potential disease activity changes. For Crohn’s patients, nicotine minimisation is the unambiguous clinical recommendation.
- Support gut microbiome health through diet: high dietary fibre from vegetables, legumes and whole grains feeds beneficial bacteria; fermented foods (kefir, yoghurt, kimchi) introduce beneficial species. These dietary approaches partially offset the microbiome compositional effects of nicotine use.
- Monitor bowel habit changes after initiating or stopping vaping — nicotine’s colonic motility effects mean that significant changes in vaping frequency can produce transit time changes that alter stool frequency and consistency. These changes are expected and usually resolve as the gastrointestinal system adapts.
- Progress toward nicotine reduction over time — the gastrointestinal case for reducing nicotine includes reflux risk, microbiome health, IBD management and carcinogenesis risk reduction, all of which improve proportionally with reduced nicotine exposure.
